CA2797058A1 - Conjugated blood coagulation factor viii - Google Patents
Conjugated blood coagulation factor viii Download PDFInfo
- Publication number
- CA2797058A1 CA2797058A1 CA2797058A CA2797058A CA2797058A1 CA 2797058 A1 CA2797058 A1 CA 2797058A1 CA 2797058 A CA2797058 A CA 2797058A CA 2797058 A CA2797058 A CA 2797058A CA 2797058 A1 CA2797058 A1 CA 2797058A1
- Authority
- CA
- Canada
- Prior art keywords
- fviii
- biocompatible polymer
- pharmaceutical composition
- bond
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1007357.5A GB201007357D0 (en) | 2010-04-30 | 2010-04-30 | Conjugated factor VIII |
| GB1007357.5 | 2010-04-30 | ||
| PCT/GB2011/000662 WO2011135307A1 (en) | 2010-04-30 | 2011-04-28 | Conjugated blood coagulation factor viii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2797058A1 true CA2797058A1 (en) | 2011-11-03 |
Family
ID=42289987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2797058A Pending CA2797058A1 (en) | 2010-04-30 | 2011-04-28 | Conjugated blood coagulation factor viii |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130150302A1 (enExample) |
| EP (1) | EP2563402A1 (enExample) |
| JP (1) | JP5870088B2 (enExample) |
| KR (1) | KR20130055619A (enExample) |
| CN (1) | CN102939108A (enExample) |
| AP (1) | AP2012006575A0 (enExample) |
| AU (1) | AU2011247147B2 (enExample) |
| BR (1) | BR112012027590A2 (enExample) |
| CA (1) | CA2797058A1 (enExample) |
| CL (1) | CL2012003039A1 (enExample) |
| CO (1) | CO6660443A2 (enExample) |
| CR (1) | CR20120579A (enExample) |
| EA (1) | EA201290938A1 (enExample) |
| EC (1) | ECSP12012314A (enExample) |
| GB (2) | GB201007357D0 (enExample) |
| IL (1) | IL222566A (enExample) |
| MX (1) | MX2012012683A (enExample) |
| MY (1) | MY160922A (enExample) |
| NI (1) | NI201200160A (enExample) |
| NZ (1) | NZ603939A (enExample) |
| PE (1) | PE20130254A1 (enExample) |
| PH (1) | PH12012502150A1 (enExample) |
| RU (1) | RU2012144555A (enExample) |
| SG (1) | SG184906A1 (enExample) |
| WO (1) | WO2011135307A1 (enExample) |
| ZA (1) | ZA201208989B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11351112B2 (en) | 2012-04-16 | 2022-06-07 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2101821T3 (da) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| BR112012001814A8 (pt) | 2009-07-27 | 2018-02-06 | Baxalta GmbH | Conjugados de proteína de coagulação sanguínea |
| ES2800983T3 (es) | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
| CN117467019A (zh) | 2018-05-18 | 2024-01-30 | 郑州晟斯生物科技有限公司 | 改进的fviii融合蛋白及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1596887B1 (en) * | 2003-02-26 | 2022-03-23 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| DK2371856T3 (en) * | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| AU2005322067B8 (en) * | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| WO2007126808A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| US20100239517A1 (en) | 2007-10-09 | 2010-09-23 | Stephen Brocchini | Novel conjugated proteins and peptides |
| KR20110016440A (ko) * | 2008-04-24 | 2011-02-17 | 셀틱 파르마 피이지 엘티디. | 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체 |
| ES2560807T3 (es) | 2008-07-21 | 2016-02-22 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| GB0912485D0 (en) * | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
-
2010
- 2010-04-30 GB GBGB1007357.5A patent/GB201007357D0/en not_active Ceased
-
2011
- 2011-04-28 SG SG2012077087A patent/SG184906A1/en unknown
- 2011-04-28 CN CN2011800218881A patent/CN102939108A/zh active Pending
- 2011-04-28 PE PE2012002104A patent/PE20130254A1/es not_active Application Discontinuation
- 2011-04-28 WO PCT/GB2011/000662 patent/WO2011135307A1/en not_active Ceased
- 2011-04-28 NZ NZ603939A patent/NZ603939A/xx not_active IP Right Cessation
- 2011-04-28 MX MX2012012683A patent/MX2012012683A/es not_active Application Discontinuation
- 2011-04-28 BR BR112012027590A patent/BR112012027590A2/pt not_active IP Right Cessation
- 2011-04-28 CA CA2797058A patent/CA2797058A1/en active Pending
- 2011-04-28 MY MYPI2012004710A patent/MY160922A/en unknown
- 2011-04-28 AU AU2011247147A patent/AU2011247147B2/en not_active Ceased
- 2011-04-28 US US13/643,287 patent/US20130150302A1/en not_active Abandoned
- 2011-04-28 EA EA201290938A patent/EA201290938A1/ru unknown
- 2011-04-28 PH PH1/2012/502150A patent/PH12012502150A1/en unknown
- 2011-04-28 AP AP2012006575A patent/AP2012006575A0/xx unknown
- 2011-04-28 KR KR1020127031386A patent/KR20130055619A/ko not_active Ceased
- 2011-04-28 JP JP2013506735A patent/JP5870088B2/ja not_active Expired - Fee Related
- 2011-04-28 EP EP11719040A patent/EP2563402A1/en not_active Withdrawn
- 2011-04-28 RU RU2012144555/15A patent/RU2012144555A/ru not_active Application Discontinuation
- 2011-04-28 GB GB201220667A patent/GB2492935B8/en not_active Expired - Fee Related
-
2012
- 2012-10-21 IL IL222566A patent/IL222566A/en not_active IP Right Cessation
- 2012-10-29 NI NI201200160A patent/NI201200160A/es unknown
- 2012-10-29 CL CL2012003039A patent/CL2012003039A1/es unknown
- 2012-11-14 CR CR20120579A patent/CR20120579A/es unknown
- 2012-11-28 ZA ZA2012/08989A patent/ZA201208989B/en unknown
- 2012-11-28 EC ECSP12012314 patent/ECSP12012314A/es unknown
- 2012-11-29 CO CO12216949A patent/CO6660443A2/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11351112B2 (en) | 2012-04-16 | 2022-06-07 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2796870A1 (en) | Conjugated blood coagulation factor viia | |
| RU2012144555A (ru) | Конъюгированный фактор свертывания крови viii | |
| JP2013525414A5 (enExample) | ||
| RU2010147813A (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
| JP2011519833A5 (enExample) | ||
| JP7483776B2 (ja) | 放出制御ｐｔｈ化合物の漸増用量設定 | |
| JP2024073467A (ja) | Ｉｌ－２コンジュゲート | |
| US12214044B2 (en) | Factor VIII zwitterionic polymer conjugates | |
| JP2025084970A (ja) | 制御放出ｐｔｈ化合物の投薬レジメン | |
| US20130261061A1 (en) | Method of enhancing efficacy of blood transfusions | |
| JP6799823B2 (ja) | ポリ（ｌ−アルギニン）セグメント含有ブロック共重合体とポリアニオン性ポリマーのポリイオンコンプレックス | |
| CN103857413A (zh) | 载体连接的曲罗尼尔前药 | |
| JP2013522239A5 (enExample) | ||
| JP2019501144A (ja) | 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法 | |
| JP2023075335A (ja) | 合成バイオコンジュゲート | |
| WO2009142326A1 (ja) | ドセタキセル高分子誘導体、並びにその製造方法及びその用途 | |
| TWI861015B (zh) | 包含抗原肽-佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物 | |
| JP2013520986A5 (enExample) | ||
| JP2011507913A5 (enExample) | ||
| Wang et al. | Absorbable microspheres sustaining epirubicin and TLR7 agonist release for transarterial chemo-immuno-embolization in liver tumor | |
| WO2012037834A1 (zh) | 一种5α-雄甾（烷）-3β，5，6β-三醇注射剂及其制备方法 | |
| JP2009149728A (ja) | ポリエーテルの製造方法 | |
| CN101405301A (zh) | 包含与粘膜粘附聚合物共价连接的药理学活性化合物的结合物以及采用该结合物的透粘膜给予药理学活性化合物的方法 | |
| CN111346235A (zh) | 一种基于弹性靶向多肽的载药纳米颗粒及其制备方法和应用 | |
| WO2009142328A1 (ja) | カンプトテシン高分子誘導体及びその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160215 |